Aspire Biopharma Completes $21 Million Private Placement Financing

Aspire Biopharma Holdings ( (ASBP) ) has issued an update.

Aspire Biopharma Holdings completed a private placement of its Series A Convertible Preferred Stock through two closings, raising a total of $21 million in gross proceeds as of April 15, 2026. The initial closing occurred on February 6, 2025, for 13,750 preferred shares and $11 million in proceeds, including the conversion of $943,801 of existing debt into equity, while a second closing on April 15, 2026, added 12,500 shares and $10 million in additional capital.

The preferred stock is immediately convertible into common shares at a discount-based formula subject to a floor price and ownership caps, following shareholder approval on April 10, 2026, for issuances above the 19.99% threshold. With the completion of the offering, Aspire Biopharma believes its stockholders’ equity now exceeds $2.5 million, the minimum required to maintain its Nasdaq Capital Market listing, and is awaiting formal confirmation from the exchange.

More about Aspire Biopharma Holdings

Aspire Biopharma Holdings, Inc. operates in the biopharmaceutical sector and is listed on The Nasdaq Capital Market. The company funds its operations through equity and convertible securities offerings, with a focus on maintaining compliance with Nasdaq’s minimum stockholders’ equity requirements to preserve its public listing and access to capital markets.

Average Trading Volume: 832,792

Technical Sentiment Signal: Sell

Current Market Cap: $2.74M

For a thorough assessment of ASBP stock, go to TipRanks’ Stock Analysis page.